[
  {
    "source": "TEP technique may carry a higher risk of conversion to another hernia repair method (either TAPP technique or open surgery) when compared to TAPP (2.5% versus 0.7%; OR 0.28, 95% CI 0.09 to 0.84, P = 0.02, I2 = 0%; 13 studies, 1178 participants; low certainty of evidence).",
    "target": "TEP technique may carry a higher risk of conversion to another hernia repair method when compared to TAPP (2.5% versus 0.7%; OR 0.28, 95% CI 0.09 to 0.84, P = 0.02, I2 = 0%; 13 studies, 1178 participants; low certainty of evidence).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "An inguinal hernia occurs when part of the intestine protrudes through the abdominal muscles. ",
    "target": "An inguinal hernia happens when the intestine sticks out through the abdominal muscles.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "There may be little to no difference between TAPP and TEP laparoscopic techniques for serious adverse events and hernia recurrence.",
    "target": "There may be little to no difference between TAPP and TEP laparoscopic methods for hernia recurrence and serious adverse events.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "TEP technique may carry a higher risk of conversion to another hernia repair method (either TAPP technique or open surgery) when compared to TAPP.",
    "target": "The TEP method may carry a higher risk of conversion to another hernia repair method (either open surgery or TAPP) when compared to TEP.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "CBT may result in a small‐to‐moderate reduction of anxiety post‐treatment (SMD ‐0.51, 95% CI ‐0.66 to ‐0.36, low‐certainty evidence). ",
    "target": "CBT may result in a small to moderate anxiety reduction after treatment (SMD ‐0.51, 95% CI ‐0.66 to ‐0.36, low evidence).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "However, compared to this benefit with CBT immediately after treatment, at three to six months post‐treatment, there was little to no difference between CBT and minimal management (SMD ‐0.29, 95% CI ‐0.59 to 0.01, low‐certainty evidence).",
    "target": "However, at three to six months after treatment, there was little to no difference between CBT and minimal management (SMD ‐0.29, 95% CI ‐0.59 to 0.01, low‐certainty evidence), compared to this benefit with CBT.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "CBT may result in a reduction of comorbid depression symptoms post‐treatment (SMD ‐0.57, 95% CI ‐0.74 to ‐0.40, low‐certainty evidence).",
    "target": "CBT may reduce depressive symptoms after treatment (SMD ‐0.57, 95% CI ‐0.74 to ‐0.40, low‐certainty evidence).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "There is not enough evidence to determine whether CBT is more effective than alternative psychological therapies for anxiety in older adults.",
    "target": "There is not enough evidence to determine whether CBT is more effective in older adults than other psychological therapies.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "To assess the effects of Cognitive Behavioural Therapy (CT, BT, CBT and third‐wave CBT interventions) on severity of anxiety symptoms compared with minimal management (not providing therapy) for anxiety and related disorders in older adults, aged 55 years or over. ",
    "target": "To assess the effects of Cognitive Behavioural Therapy (CT, BT, CBT and third‐wave CBT interventions) in older adults, aged 55 years or over, on severity of anxiety symptoms compared with minimal management (not providing therapy).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Percutaneous and surgical interventions combined with albendazole can be used to treat uncomplicated hepatic cystic echinococcosis; however, there is a scarcity of randomised evidence directly comparing these interventions. ",
    "target": "Percutaneous and surgical treatments with albendazole can be used to treat simple hepatic cystic echinococcosis. || However, there is not enough randomised evidence directly comparing these treatments.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "To evaluate the benefits and harms of preoperative statin therapy in adults undergoing cardiac surgery compared to standard of care or placebo. ",
    "target": "To evaluate the benefits and risks of preoperative statin therapy in adults undergoing heart surgery against placebo or standard care. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "We included all randomised controlled trials (RCTs) comparing any statin treatment before cardiac surgery, for any given duration and dose, versus no preoperative statin therapy (standard of care) or placebo. ",
    "target": "We included all randomised controlled trials (RCTs) comparing any statin therapy before heart surgery, for any given dose and duration, versus placebo or no statin therapy (standard of care).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "We excluded trials without a registered trial protocol and trials without approval by an institutional ethics committee. ",
    "target": "We did not include trials that did not have a registered trial protocol or without institutional approval. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Statins probably result in little to no difference in myocardial infarction (RR 0.88, 95% CI 0.73 to 1.06; I2 = 0%; 5 RCTs, 4645 participants; moderate‐certainty evidence), may result in little to no difference in atrial fibrillation (RR 0.87, 95% CI 0.72 to 1.05; I2 = 60%; 8 RCTs, 5592 participants; low‐certainty evidence), and may result in little to no difference in stroke (RR 1.47, 95% CI 0.90 to 2.40; I2 = 0%; 4 RCTs, 5143 participants; low‐certainty evidence).",
    "target": "Statins probably result in little to no difference in atrial fibrillation (RR 0.87, 95% CI 0.72 to 1.05; I2 = 60%; 8 RCTs, 5592 participants; low‐certainty evidence), and may result in little to no difference in myocardial infarction (RR 0.88, 95% CI 0.73 to 1.06; I2 = 0%; 5 RCTs, 4645 participants; low‐certainty evidence).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Vitamin D supplementation during pregnancy may help improve maternal and neonatal health outcomes (such as fewer preterm birth and low birthweight babies) and reduce the risk of adverse pregnancy outcomes (such as severe postpartum haemorrhage). ",
    "target": "Vitamin D supplementation during pregnancy may help improve maternal and neonatal health outcomes (such as fewer preterm birth and low birthweight babies) and reduce the risk of serious complications during pregnancy.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Selection criteria: Randomised and quasi‐randomised trials evaluating the effect of supplementation with vitamin D alone or in combination with other micronutrients for women during pregnancy in comparison to placebo or no intervention. ",
    "target": "Selection criteria: Randomised and quasi‐randomised trials to evaluate the effect of vitamin D supplementation in women during pregnancy on other micronutrients compared to placebo or no intervention.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The evidence is very uncertain about the effect of supplementation with vitamin D during pregnancy compared to placebo or no intervention on pre‐eclampsia (risk ratio (RR) 0.53, 95% confidence interval (CI) 0.21 to 1.33; 1 study, 165 women), gestational diabetes (RR 0.53, 95% CI 0.03 to 8.28; 1 study, 165 women), preterm birth (< 37 weeks) (RR 0.76, 95% CI 0.25 to 2.33; 3 studies, 1368 women), nephritic syndrome (RR 0.17, 95% CI 0.01 to 4.06; 1 study, 135 women), or hypercalcaemia (1 study; no cases reported).",
    "target": "The evidence is very uncertain about the effect of vitamin D during pregnancy (risk ratio (RR) 0.53, 95% confidence interval (CI) 0.21 to 1.33; 1 study, 165 women), preterm birth (RR 0.76, 95% CI 0.25 to 2.33; 3 studies, 1368 women), nephritic syndrome (RR 0.17, 95% CI 0.01 to 4.06; 1 study, 135 women), or hypercalcaemia (1 study; no cases reported).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Supplementation with vitamin D during pregnancy may reduce the risk of severe postpartum haemorrhage; however, only one study reported this outcome (RR 0.68, 95% CI 0.51 to 0.91; 1 study, 1134 women; low‐certainty evidence) and may reduce the risk of low birthweight; however, the upper CI suggests that an increase in risk cannot be ruled out (RR 0.69, 95% CI 0.44 to 1.08; 3 studies, 371 infants; low‐certainty evidence). ",
    "target": "Supplementation with vitamin D during pregnancy may reduce the risk of severe postpartum haemorrhage; however, only one study reported this outcome (1 study, 1134 women; low-certainty evidence) and the upper CI does not rule out an increase in risk.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The evidence is very uncertain about the effect of supplementation with vitamin D and calcium on preterm birth (RR not estimable; very low‐certainty evidence) or for low birthweight (RR 1.45, 95% CI 0.14 to 14.94; very low‐certainty evidence) compared to women who received placebo or no intervention. ",
    "target": "The evidence is very uncertain about the effect of calcium and vitamin D supplementation on low birthweight (RR 1.45, 95% CI 0.14 to 14.94; very low‐certainty evidence) and preterm birth compared to women who received placebo or no intervention.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Feeding via a tube misplaced in the trachea can result in severe pneumonia.",
    "target": "Feeding through a tube in the trachea can cause serious pneumonia.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The objective was to assess the diagnostic accuracy of ultrasound alone or in combination with other methods for gastric tube placement confirmation in children and adults. ",
    "target": "The goal was to determine the diagnostic accuracy of ultrasound alone or together with other gastric tube placement methods in adults and children. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Based on limited evidence, ultrasound does not have sufficient accuracy as a single test to confirm gastric tube placement.",
    "target": "Based on limited evidence, ultrasound does not have sufficient accuracy to confirm the placement of the gastric tube.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Our 2009 Cochrane review found that calcium channel blockers (CCBs) improved graft function and prevented graft loss, while the evidence for other BP‐lowering treatments was limited. ",
    "target": "Our 2009 Cochrane review found that calcium channel blockers (CCBs) improved graft function and prevented graft loss. || However, the evidence was limited for other treatments.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Randomised controlled trials (RCTs) and quasi‐RCTs evaluating any BP‐lowering agent in recipients of a functioning kidney transplant for at least two weeks were eligible",
    "target": "Randomised controlled trials (RCTs) and quasi‐RCTs were conducted in recipients of a functioning kidney transplant for at least two weeks.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Compared to placebo or standard care alone, CCBs probably reduce all‐cause death and graft loss.",
    "target": "Compared to standard care alone, CCBs probably reduce graft loss and all-cause death.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The effects of CCBs, ACEi or ARB compared to placebo or standard care alone on cardiovascular outcomes (including fatal or nonfatal myocardial infarction, fatal or nonfatal stroke) or other adverse events were uncertain. ",
    "target": "The effects of CCBs, ACEi or ARB compared to placebo or standard care alone on cardiovascular outcomes (fatal or nonfatal myocardial infarction, stroke or other adverse events) were not known.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "For kidney transplant recipients, the use of CCB therapy to reduce BP probably reduces death and graft loss compared to placebo or standard care alone, while ARB may reduce graft loss",
    "target": "For kidney transplant recipients, the use of CCB therapy to reduce BP probably reduces death and graft loss compared to placebo. || ARB may also help with graft loss.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Cell transplantation offers a potential therapeutic approach to the repair and regeneration of damaged vascular and cardiac tissue after acute myocardial infarction (AMI). ",
    "target": "Cell transplantation offers a potential therapeutic approach after acute myocardial infarction (AMI) to repair and regenerate damaged vascular tissue.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Normal pressure hydrocephalus (NPH) occurs when the brain ventricles expand, causing a triad of gait, cognitive, and urinary impairment.",
    "target": "Normal pressure hydrocephalus (NPH) happens when the brain ventricles expand. || This causes walking, cognitive, and urinary problems.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "It can occur after a clear brain injury such as trauma, but can also occur without a clear cause (termed idiopathic, or iNPH). ",
    "target": "It can happen after a clear brain injury, such as trauma. || It can also happen without a clear cause, called idiopathic.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Non‐randomised studies have shown a benefit from surgically diverting ventricular fluid to an area of lower pressure by cerebrospinal fluid (CSF)‐shunting in iNPH, but historically there have been limited randomised controlled trial (RCT) data to confirm this. ",
    "target": "Non-randomised studies have shown a benefit from surgically diverting cerebrospinal fluid (CSF) to an area of lower pressure in iNPH. || However, there have been limited randomised controlled trial (RCT) data to confirm this.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "CSF‐shunting probably improves gait speed at less than six months post‐surgery .",
    "target": "CSF‐shunting probably improves gait speed less than six months after surgery.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "CSF‐shunting may improve qualitative gait function at less than six months post‐surgery by an uncertain amount ",
    "target": "CSF‐shunting may improve quality of life at less than six months after surgery by an unknown amount ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The evidence is very uncertain about the effect of CSF‐shunting on cognitive function at less than six months post‐CSF‐shunt surgery.",
    "target": "The effect of CSF‐shunting on cognitive function is not known at less than six months after CSF‐shunt surgery.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. ",
    "target": "Eczema (atopic dermatitis) is the most common skin disease in the world and can not be prevented or cured. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The objective was to compare and rank the efficacy and safety of topical anti‐inflammatory treatments for people with eczema using a network meta‐analysis. ",
    "target": "The aim was to compare and rank the safety and efficacy of topical anti-inflammatory treatments for eczema in people with eczema. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high‐income countries in secondary care settings.",
    "target": "We included 291 studies involving 45,846 people with a wide range of eczema severity. || Most were done in high-income countries in secondary care settings.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Treatment duration and trial participation were a median of 21 and 28 days (ranging from 7 days to 5 years), respectively.",
    "target": "The trial duration and treatment duration were a median of 21 and 28 days, respectively, ranging from 7 days to 5 years.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "NMA of 25 trials reporting skin thinning found no evidence for increased skin thinning with short‐term (median 3 weeks, range 1‐16 weeks) use of mild TCS, moderate TCS, potent TCS, or very potent TCS , all with low confidence.",
    "target": "NMA of 25 trials reporting skin thinning found no evidence for increased skin thinning with mild TCS, moderate TCS, potent TCS, or very potent TCS , all with low confidence (median 3 weeks, range 1‐16 weeks).",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The prevalence of tobacco use among people living with HIV (PLWH) is up to four times higher than in the general population.",
    "target": "Tobacco use among people living with HIV (PLWH) is up to four times more common than in the general population.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The objective was to assess the benefits, harms and tolerability of interventions for tobacco use cessation among people living with HIV. ",
    "target": "The aim of the study was to determine the benefits, harms and tolerability of tobacco cessation among people living with HIV. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "We included randomised controlled trials (RCTs) of individual‐/group‐level behavioural or pharmacological interventions, or both, for tobacco use cessation, delivered directly to PLWH aged 18 years and over, who use tobacco.",
    "target": "We included randomised controlled trials (RCTs) of individual‐/group‐level behavioural or pharmacological interventions, delivered directly to PLWH aged 18 years and over, to help them stop using tobacco.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "We also included RCTs, quasi‐RCTs, other non‐randomised controlled studies (e.g. controlled before and after studies), and interrupted time series studies of system‐change interventions for tobacco use cessation among PLWH. ",
    "target": "We also included RCTs, quasi‐RCTs, other non‐randomised controlled studies (e.g. || before and after studies), and interrupted time series studies of PLWH. || The results of these studies are published here.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Low‐certainty evidence did not demonstrate a clear benefit for tobacco use cessation rates in PLWH randomised to receive behavioural support compared with brief advice or no intervention.",
    "target": "There was no clear benefit for tobacco use cessation rates in PLWH randomised to receive behavioural support compared with short advice or no intervention.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Moderate‐certainty evidence suggested that varenicline may help more PLWH to quit smoking than placebo with no evidence of heterogeneity.",
    "target": "Moderate evidence suggests that varenicline may help more PLWH to stop smoking than placebo. || However, there was no heterogeneity.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Low‐certainty evidence did not detect a difference between varenicline and placebo in the proportion of participants experiencing SAEs.",
    "target": "No difference was found between varenicline and placebo when it came to the proportion of participants experiencing SAEs.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "No studies assessed SAEs for the following: behavioural support plus NRT versus brief advice; varenicline versus NRT and cytisine versus NRT. ",
    "target": "No studies assessed SAEs for the following: short advice versus behavioural support; varenicline versus NRT and cytisine versus NRT. || ",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Repetitive transcranial magnetic stimulation (rTMS) is a non‐invasive therapy involving induction of electrical currents in cortical brain tissue.",
    "target": "Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment. || It uses electric current to stimulate the brain.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "Current pharmacological and psychotherapeutic treatments for PTSD are associated with inadequate symptom improvement and high dropout rates. ",
    "target": "Current psychotherapeutic and pharmacological treatments for PTSD are associated with high dropout rates and poor symptom improvement.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  },
  {
    "source": "The evidence is very uncertain about the effect of active rTMS on serious adverse events.",
    "target": "The evidence is not clear whether active rTMS can cause serious adverse events.",
    "metadata": {
      "annotator": "annotator_0",
      "system": "MUSS"
    },
    "edits": []
  }
]